Table 1 Baseline characteristics of the intention-to-treat (ITT) population with osteoarthritis of the knee
Risedronate | ||||
|---|---|---|---|---|
Characteristic | Placebo (n = 98) | 5 mg/day (n = 96) | 15 mg/day (n = 90) | P |
Age (years) | 63.2 (0.82) | 62.9 (0.90) | 63.8 (0.88) | 0.652a |
Height (cm) | 164.3 (0.90) | 165.3 (0.97) | 165.1 (0.93) | 0.614a |
Body mass index (kg/m2) | 29.2 (0.38) | 29.0 (0.40) | 29.2 (0.42) | 0.799a |
Sex (no. (%)) | 0.307b | |||
Male | 34 (35%) | 40 (42%) | 41 (46%) | |
Female | 64 (65%) | 56 (58%) | 49 (54%) | |
Post-menopausal (no. (%)) | 54 (84%) | 49 (88%) | 43 (88%) | 0.985b |
Years since menopause | 14.4 (1.22) | 16.5 (1.57) | 17.4 (1.42) | 0.273a |
Oestrogen or SERM use (no. (%)) | 18 (28%) | 15 (27%) | 10 (20%) | 0.380b |
Race (no.) | 0.385b | |||
Asian Oriental | 1 | 0 | 0 | |
Asian Indian | 1 | 0 | 2 | |
Caucasian | 96 | 96 | 88 | |
Joint-space width (mm) | 3.03 (0.05) | 2.95 (0.05) | 3.01 (0.06) | 0.577a |
WOMAC – weighted total score | 50.3 (2.0) | 46.1 (2.0) | 49.4 (2.4) | 0.281a |
Use of walking aids (no. (%)) | 16 (16) | 22 (23) | 12 (13) | 0.224b |
uCTX-II (ng/mmol creatinine) | 312.5 (19.9) | 328.9 (29.7) | 340.1 (24.0) | 0.748a |
uNTX-I (nmol/mmol creatinine) | 40.3 (2.8) | 42.3 (4.5) | 38.6 (2.2) | 0.954a |